<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153525</url>
  </required_header>
  <id_info>
    <org_study_id>34409/1/21</org_study_id>
    <nct_id>NCT05153525</nct_id>
  </id_info>
  <brief_title>Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS</brief_title>
  <official_title>Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to compare continuous infusion vs on need intermittent boluses of&#xD;
      Cisatracurium in the early management of pediatric acute respiratory distress syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the pediatric population, Acute respiratory distress syndrome (ARDS) has a high mortality&#xD;
      rate of approximately 24%. In addition, there is a lack of high-quality data to guide the use&#xD;
      of non-depolarizing neuromuscular blocking agents (NMBAs) in mechanically ventilated&#xD;
      children. Hence, there is a need to evaluate its use in pediatrics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration on mechanical ventilation</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Time from patient's intubation till extubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of PICU stay</measure>
    <time_frame>28 days</time_frame>
    <description>Time from start of ventilation till discharge from PICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>28 days</time_frame>
    <description>Time from start of ventilation till discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PICU acquired weakness</measure>
    <time_frame>28 days</time_frame>
    <description>Manual muscle strength testing (Oxford testing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure free days to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Organ failure according to SOFA scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation follow-up</measure>
    <time_frame>7 days</time_frame>
    <description>Oxygenation Index/Oxygen saturation index on study days 1, 3, 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All children died after mechanical ventilation till day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Interleukin-8 assessment</measure>
    <time_frame>48 hours</time_frame>
    <description>Assessing serum interleukin 8 on admission and after 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation complications follow-up</measure>
    <time_frame>28 days</time_frame>
    <description>Development of pneumothorax during mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Respiratory Distress Syndrome, Pediatric</condition>
  <condition>Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)</condition>
  <arm_group>
    <arm_group_label>Intermittent boluses group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirty children with ARDS will be managed with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous infusion for 24 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermittent boluses of Cisatracurium</intervention_name>
    <description>Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).</description>
    <arm_group_label>Intermittent boluses group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous infusion of Cisatracurium for 24 hours</intervention_name>
    <description>Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.</description>
    <arm_group_label>Intravenous infusion for 24 hours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children with mild, moderate, and severe ARDS diagnosed according to criteria of&#xD;
             Pediatric Acute Lung Injury Consensus Conference (PALICC) in 2015.&#xD;
&#xD;
          2. Children of both sexes aged from one month to 18 years.&#xD;
&#xD;
          3. Children diagnosed with ARDS &lt;48 hours before enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Continuous neuromuscular blockade at enrollment&#xD;
&#xD;
          2. Children on phenytoin and carbamazepine&#xD;
&#xD;
          3. Severe liver cirrhosis&#xD;
&#xD;
          4. High-risk medical illness (Bone marrow transplantation within the last one-year,&#xD;
             Diffuse alveolar hemorrhage from vasculitis, Chronic respiratory failure, Burns &gt; 70%&#xD;
             total body surface)&#xD;
&#xD;
          5. Previous hypersensitivity or anaphylactic reaction to Cisatracurium&#xD;
&#xD;
          6. Neuromuscular conditions that may potentiate neuromuscular blockade and/or impair&#xD;
             effective spontaneous ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Khaled Talaat, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Khaled Talaat, PharmD</last_name>
    <phone>00201067967640</phone>
    <email>mohamedktalaat@pharm.tanta.edu.eg</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Mohamed Khaled Talaat</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cisatracurium</keyword>
  <keyword>PARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisatracurium</mesh_term>
    <mesh_term>Atracurium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be available upon reasonable request from the principal investigator</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>for one year after completion of the study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

